Sanofi (NYSE:SNY) was downgraded by Morgan Stanley from an “overweight” rating to an “underweight” rating in a research report issued to clients and investors on Friday.
Several other equities research analysts have also recently issued reports on SNY. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. raised Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Finally, Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $53.50.
Shares of Sanofi (SNY) opened at $44.62 on Friday. Sanofi has a fifty-two week low of $38.45 and a fifty-two week high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The company has a market capitalization of $112,509.69, a P/E ratio of 14.08, a P/E/G ratio of 2.46 and a beta of 0.86.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.